Danish Biotech Startup Alcolase Secures €1.5M to Develop Enzyme Treatment for Genetic Alcohol Intolerance
Danish biotech startup Alcolase raised €1.5 million to develop an enzyme-based technology that breaks down alcohol in the stomach before absorption, targeting the 540 million people in East Asia with ALDH2 deficiency (genetic alcohol intolerance). The company plans to launch in Singapore and South Korea, with a UK subsidiary supporting therapeutic drug delivery development.